A Phase 3, Long-term, Open-label Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Istradefylline (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin
- 13 Mar 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.
- 13 Mar 2017 Planned primary completion date changed from 1 Jul 2017 to 16 Nov 2017.
- 09 Dec 2016 Status changed from recruiting to active, no longer recruiting.